Mesothelioma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BAP1 4
• PD-1 6
• TP53 0
• PD-L1 4
• YAP 0
• CDKN2A 0
• CTLA-4 2
• AXL 0
• B7-H3 0
• MDM2 0
• MET 0
• PRMT5 3
• VEGF 1
• AKT 0
• BRCA1 0
• EGFR 1
• EZH2 0
• FAK 0
• HMGB1 0
• NRF2 0
• PARP 0
• STAT3 0
• STK11 0
• TROP2 0
• AMPK 0
• ARID1A 1
• BRAF 0
• BRCA2 0
• CD30 0
• CD40 0
• CDK4/6 0
• GPC3 1
• IDH 0
• IL-17 0
• IL-6 0
• JNK 0
• LAG-3 1
• mTOR 0
• MUC1 0
• NTRK 1
• PI3K 0
• STING 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 410 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Suspended

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Updated 13 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Suspended

  Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

  NCT05703854· M.D. Anderson Cancer Center· Updated 31 Jul 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

  NCT05714553· NuCana plc· Updated 23 Jul 2026

  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

  NCT03075527· Dana-Farber Cancer Institute· Updated 16 Jul 2026

  “Criteria not met for second stage at time of interim analysis”Registry text, quoted unchanged. Source

• Terminated

  Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

  NCT04158141· NRG Oncology· Updated 13 Jul 2026

  “Permanent Administrative Closure”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

  NCT05451849· TCR2 Therapeutics· Updated 13 Jul 2026

  “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.”Registry text, quoted unchanged. Source

• Terminated

  A Study of SGN-MesoC2 in Advanced Solid Tumors

  NCT06466187· Seagen, a wholly owned subsidiary of Pfizer· Updated 7 Jul 2026

  “The trial was terminated for strategic reasons. The decision was not based on any safety concerns”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

  NCT06885697· National Cancer Institute (NCI)· Source

• Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

  NCT04431024· National Cancer Institute (NCI)· Source

• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

  NCT06503146· National Cancer Institute (NCI)· Source

• Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

  NCT04577326· Memorial Sloan Kettering Cancer Center· Source

• Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

  NCT05001880· National Cancer Institute (NCI)· Source

• Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

  NCT07892300· Oliver Jonas· Source

• MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

  NCT06097728· AstraZeneca· Source

• Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1

  NCT03830229· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Organoids 3
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 6
• Exome Sequencing 3
• Proteomics 8
• Mass Spectrometry 3
• Flow Cytometry 6
• Immunohistochemistry 26
• Xenograft Model Antitumor Assays 21
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 3
• Machine Learning 6
• Deep Learning 1
• Cohort Studies 10
• Genome-Wide Association Study 3

• MesoRet: a reticulin stain-based deep learning algorithm to assist diffuse mesothelioma subtyping.

  Pathologica, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.